Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Dresden – page 32

954 clinical trials in Dresden, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dresden at a glance
954
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

954 trials in Dresden

Open in trial search

Malignant lymphoid neoplasm

Recruiting

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Breast cancer

Recruiting

Study on Post-Neoadjuvant Therapy for Early Breast Cancer Using Ipatasertib, Inavolisib, and Atezolizumab for Patients with High-Risk Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Chronic kidney disease

Recruiting

Study on Dapagliflozin and Lifestyle Changes for Patients with Early Chronic Kidney Disease and Prediabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Synovial sarcoma+2

Recruiting

Study of Personalized Peptide Vaccine with PERVI-FUS, PERVI-NEO, and 11902A for Children and Young Adults with Metastatic Fusion-Driven Sarcomas

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Pervi-Fus
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Juvenile spondyloarthritis+2

Recruiting

Study on the Safety and Body Processing of Bimekizumab in Children with Juvenile Idiopathic Arthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Acute myeloid leukaemia

Recruiting

Study Comparing Venetoclax and Azacitidine with Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutations Eligible for Intensive Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Technische Universitaet Dresden

Retinopathy of prematurity

Recruiting

Study on Oral Propranolol for Preventing Severe Retinopathy in Premature Infants

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Propranolol Hydrochloride
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Adenocarcinoma gastric+1

Recruiting

Study on the Effectiveness of Oxaliplatin, Docetaxel, and Fluorouracil in Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Krankenhaus Nordwest GmbH

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Not yet recruiting
Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Regeneron Pharmaceuticals Inc.

Peripheral arterial occlusive disease

Not yet recruiting

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Regn7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Dresden

What the registry says about research in the country

01 Respiratory Disease Research

Innovative clinical trials focusing on respiratory infections and preventive treatments, including studies of vaccines against RSV and human metapneumovirus in older adults.

  • Respiratory Syncytial Virus Prevention
  • Chronic Rhinosinusitis Treatment
  • Viral Respiratory Infections

Multiple studies evaluating both therapeutic and preventive approaches for respiratory conditions.

02 Oncology Studies

Comprehensive research into various cancer types, including trials for breast cancer, gastric cancer, and pancreatic cancer treatments.

  • Advanced Cancer Therapeutics
  • Targeted Cancer Treatments
  • Immunotherapy Research

Focus on innovative treatment approaches and combination therapies for various cancer types.

03 Autoimmune Conditions

Studies examining treatments for various autoimmune disorders, including psoriatic arthritis and plaque psoriasis.

  • Inflammatory Disease Management
  • Novel Therapeutic Approaches
  • Chronic Disease Treatment

Investigation of new therapeutic options for patients with autoimmune and inflammatory conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.